ArticleThe Journal of experimental medicine2017
MicroRNA regulation of type 2 innate lymphoid cell homeostasis and function in allergic inflammation.
Article in The Journal of experimental medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 81 citations in OpenAlex.
- Exploration of miRNAs promoting eosinophilia and type 2 immunity.Frontiers in allergy · 2026Article
- USP18 confers protection against allergic asthma by suppressing CCL8 production in alveolar type II epithelial cells.Respiratory research · 2025Article
- Non-Coding RNAs in Asthma: Regulators of Eosinophil Biology and Airway Inflammation.Diagnostics (Basel, Switzerland) · 2025Review
- Studies on the role of non-coding RNAs in controlling the activity of T cells in asthma.Non-coding RNA research · 2023Review
- Regulation of noncoding RNAs in innate lymphoid cells.Cellular & molecular immunology · 2023Article
- The ins and outs of innate and adaptive type 2 immunity.Immunity · 2023Review
- Alarmins and MicroRNAs, a New Axis in the Genesis of Respiratory Diseases: Possible Therapeutic Implications.International journal of molecular sciences · 2023Review
- Current research into A20 mediation of allergic respiratory diseases and its potential usefulness as a therapeutic target.Frontiers in immunology · 2023Review
- Article
- Article
- MiR-19 Family Impairs Adipogenesis by the Downregulation of the PPARγ Transcriptional Network.International journal of molecular sciences · 2022Article
- RNA-binding protein RBM3 intrinsically suppresses lung innate lymphoid cell activation and inflammation partially through CysLT1R.Nature communications · 2022Article
- Review
- Review
- MiR-150-5p regulates the functions of type 2 innate lymphoid cells via the ICAM-1/p38 MAPK axis in allergic rhinitis.Molecular and cellular biochemistry · 2022Article
- N6-methyladenosine-dependent modification of circGARS acts as a new player that promotes SLE progression through the NF-κB/A20 axis.Arthritis research & therapy · 2022Article
- Role of microRNAs in type 2 diseases and allergen-specific immunotherapy.Frontiers in allergy · 2022Review
- Review
- Epithelial miR-206 targets CD39/extracellular ATP to upregulate airway IL-25 and TSLP in type 2-high asthma.JCI insight · 2021Article
- Spotlight on microRNAs in allergy and asthma.Allergy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
MicroRNAs (miRNAs) exert powerful effects on immunity through coordinate regulation of multiple target genes in a wide variety of cells. Type 2 innate lymphoid cells (ILC2s) are tissue sentinel mediators of allergic inflammation. We established the physiological requirements for miRNAs in ILC2 homeostasis and immune function and compared the global miRNA repertoire of resting and activated ILC2s and T helper type 2 (T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.